跳至主要内容
临床试验/NCT02685189
NCT02685189终止不适用

Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)(WS)(ISNHP)

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company0 个研究点目标入组 55 人开始时间: 2006年7月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
55
主要终点
NEUROLOGICAL EXAMINATION; Child Behavior Check List

研究概览

简要总结

The purpose of this protocol is to provide a mechanism to collect Long Term Clinical Data from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion".

详细描述

The purpose of this protocol is to provide a mechanism to collect Clinical Data from those babies who participated in the primary Study 64,185-06-2(W)(WS)(ISNHP) "An Open-Label Study Of The Safety And Clinical Pharmacology Of Stanate® In Infants At-Risk For Exchange Transfusion". Data on long-term impact of Stannsoporfin on the physical, neurological, neurodevelopmental, biochemical, metabolic and hematopoietic profiles of the children will be collected at 9 and 18 months, 3, 6 and 9 years after Stannsoporfin administration

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Day 至 60 Days(Child)
性别
All
接受健康志愿者

入选标准

  • All children who have been enrolled and received Stanate® Injection/Placebo in Study Protocol 64,185-06-2(W)(WS)(ISNHP) are eligible for this follow-up.

排除标准

  • 未提供

结局指标

主要结局

NEUROLOGICAL EXAMINATION; Child Behavior Check List

时间窗: 10 years

Child Behavior Check List is a standardized measure in child psychology for evaluating maladaptive behavioral and emotional problems in preschool patients

次要结局

未报告次要终点

研究者

发起方
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
申办方类型
Industry
责任方
Sponsor

相似试验